Trials / Completed
CompletedNCT02962310
Bio Equivalence Study of Torrent Pharmaceutical Ltd's Rosuvastatin Calcium Tablets Under Fasting Condition.
An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE of Rosuvastatin Ca Tab 40 mg [Torrent,India] Versus Crestor 40 mg Tab [ AstraZeneca Pharmaceuticals LP, USA] in Healthy Subjects-Fasted Condition.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Torrent Pharmaceuticals Limited · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of studies were separated by a washout period of 7 days.
Detailed description
An Open Label, Randomized, 2-period, 2- Treatment, 2-Sequence, Crossover, Single-dose Bioequivalence Study of Rosuvastatin Calcium Tablets containing Rosuvastatin Calcium 40 mg ( Test Formulation, Torrent Pharmaceutical Ltd., India) Versus Crestor® 40 mg Tablets containing Rosuvastatin Calcium 40 mg (Reference , AstraZeneca Pharmaceuticals LP, USA) in Healthy Human Volunteers Under Fasting Condition.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Torrent's Rosuvastatin Calcium Tablets 40 mg | oral, crossover |
| DRUG | Crestor 40 mg Tablets of AstraZeneca LP, USA | oral, crossover |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2009-11-01
- Completion
- 2009-11-01
- First posted
- 2016-11-11
- Last updated
- 2016-11-11
Source: ClinicalTrials.gov record NCT02962310. Inclusion in this directory is not an endorsement.